Pasithea Therapeutics
KTTA
19 hedge funds and large institutions have $441K invested in Pasithea Therapeutics in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
104% more capital invested
Capital invested by funds: $217K → $441K (+$225K)
73% more funds holding
Funds holding: 11 → 19 (+8)
4.19% more ownership
Funds ownership: 4.04% → 8.23% (+4.2%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$46.9K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39.3K |
| 3 |
Two Sigma Investments
New York
|
+$26.1K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$25.1K |
| 5 |
Renaissance Technologies
New York
|
+$22.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$17.4K |
| 2 |
LPL Financial
San Diego,
California
|
-$7.21K |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
-$1.14K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$32 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$3 |
KTTA Hedge Fund Activity: Q3 2025 in Review
19 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q3 2025, worth a combined $441K — up 104% from $217K a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new KTTA positions and 2 closed out — a net gain of 8 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $46.9K. The largest seller was UBS Group, cutting an estimated $17.4K.
- 19 institutional investors held Pasithea Therapeutics (KTTA) as of Q3 2025, up from 11 in Q2 2025.
- Funds reported $441K of Pasithea Therapeutics stock for Q3 2025, up 104% quarter-over-quarter.
- 10 funds opened new Pasithea Therapeutics positions in Q3 2025 and 2 closed out, a net change of +8 holders.
- The largest Pasithea Therapeutics buyer in Q3 2025 was AdvisorShares Investments, an estimated $46.9K added.
- The largest Pasithea Therapeutics seller in Q3 2025 was UBS Group, an estimated $17.4K sold.
Based on aggregated 13F filings for Q3 2025.